Is verapamil a double-edged sword in rate control of paroxysmal atrial fibrillation?
Raatikainen
M J Pekka
MJ
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000139:chemically induced* / Q000188:drug therapy / Q000209:etiology; D001283:Atrioventricular Node / Q000187:drug effects; D006325:Heart Atria / Q000187:drug effects / Q000294:innervation / Q000473:pathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D011667:Pulmonary Veins / Q000187:drug effects* / Q000294:innervation / Q000473:pathology; D014700:Verapamil / Q000009:adverse effects* / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D014700:Verapamil